Examining how lung cancer lesions shrink after radiotherapy

Exploration of and Model Establishment of the Regression Pattern of Primary Lesions in Lung Cancer After Definitive Radiotherapy

This study looks at how lung cancer tumors shrink after radiation treatment to help improve future care for patients with lung cancer.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: China-Japan Friendship Hospital (Academic / other)
• Drugs / interventions: radiation
• Locations: 2 sites (Beijing, Beijing Municipality and 1 other locations)
• Trial ID: NCT06692972 on ClinicalTrials.gov

What this trial studies

This observational study aims to analyze the regression patterns of primary lung cancer lesions following definitive radiotherapy. By retrospectively collecting clinical data from patients who have undergone this treatment, the study will utilize imaging tools to measure changes in tumor size and volume. The goal is to establish a model for tumor regression and evaluate the relationship between regression rates, adverse effects, and patient prognosis. This research seeks to optimize radiotherapy plans to enhance treatment efficacy for lung cancer patients.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with stage II-III lung cancer who have not undergone prior surgery and have received definitive radiotherapy.

Not a fit: Patients who have had prior local treatments such as surgery or have not completed their radiotherapy plan may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved radiotherapy strategies that enhance treatment outcomes for lung cancer patients.

How similar studies have performed: While this study explores a specific aspect of tumor regression in lung cancer, similar studies have shown promise in optimizing radiotherapy approaches.

Eligibility criteria

Inclusion Criteria:

1. Age ≥18 years old;
2. Stage II-III lung cancer with a clear pathological diagnosis report or medical record, not undergoing surgery before radiotherapy;
3. The primary lung lesion received definitive radiotherapy (defined as conventional fractionation radiotherapy with dose ≥50Gy, stereotactic radiotherapy with biologically effective dose ≥100Gy);
4. The target lesion of the lung receiving radiotherapy can be measured;
5. Imaging data can be obtained before and after radiotherapy;
6. Complete radiotherapy as planned, or the actual received dose has reached the defined definitive dose.

Exclusion Criteria：

1. Before radiotherapy, the primary lesion of the lung had received local treatment such as surgery or ablative treatment;
2. The radiotherapy plan was not completed, and the actual dose received did not reach the definitive dose (defined as conventional fractionation radiotherapy with dose \<50Gy, stereotactic radiotherapy with biologically effective dose \<100Gy)；
3. Required imaging data cannot be obtained;
4. Other conditions considered by the investigator to be inappropriate for enrollment.

Where this trial is running

Beijing, Beijing Municipality and 1 other locations

• China-Japan Friendship Hospital — Beijing, Beijing Municipality, China (Recruiting)
• Renmin Hospital of Wuhan University — Wuhan, Hubei, China (Recruiting)

Study contacts

• Principal investigator: Guangying Zhu, M.D. — China-Japan Friendship Hospital
• Study coordinator: Guangying Zhu, M.D.

Conditions Lung Cancer; lung cancer; radiotherapy